Clinical Trials Logo

Heart Failure NYHA Class I clinical trials

View clinical trials related to Heart Failure NYHA Class I.

Filter by:
  • None
  • Page 1

NCT ID: NCT06394986 Completed - Heart Failure Clinical Trials

Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction

Start date: June 18, 2018
Phase:
Study type: Observational

This is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session after a "long" interdialysis interval.

NCT ID: NCT04829617 Recruiting - Heart Failure Clinical Trials

Promoting Well-being and Health in Heart Failure

Start date: November 29, 2021
Phase: N/A
Study type: Interventional

The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks), compared to an attention-matched MI-based educational condition, in a randomized trial (NIH Stage II) of 280 patients with New York Heart Association class I-III Heart Failure (HF).

NCT ID: NCT04741191 Completed - Clinical trials for Heart Failure NYHA Class II

Cycle Ergometer Training and Heart Failure on Heart Rate Recovery and Mind Fullness

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

To evaluate the effects of cycle ergometer training on heart rate recovery in Newyork Heart Association (NYHA) class I and II heart patients. To evaluate the effects of cycle ergometer training on mind fullness in NYHA class I and II heart patients. Previous studies were designed to target only cardiac functions and no psychological aspect was studied so this study cover this aspect as well so from the outcomes of this study we can determine both psychological satisfaction and cardiac function as well.

NCT ID: NCT03895073 Completed - Heart Failure Clinical Trials

HEart fAiluRe evaluaTion Questionnaire

HEART
Start date: September 1, 2018
Phase:
Study type: Observational

The "four-point" questionnaire by Severo and his associates was weighted in 2011 in the Portuguese population and aims to characterize the severity of the symptoms of heart failure by providing a way to minimize the reliability of the NYHA classification. The questionnaire consists of four closed questions, three possible single-choice answers, coded 0, 1 or 2, and has been translated into Greek in accordance with the internationally-based methodology, with forward-backward translation.

NCT ID: NCT03388918 Completed - Clinical trials for Acute Decompensated Heart Failure

Future Patient - Telerehabilitation of Heart Failure Patients

Start date: December 21, 2016
Phase: N/A
Study type: Interventional

The idea behind the Future Patient research project is to develop a telerehabilitation program and tools for patients with heart failure. The hypothesis for this study is that participation in a telerehabilitation program for patients with heart failure will increase the patients' quality of life and multi-parametric (subjective and objective) individualized monitoring in a telerehabilitation program for patients with heart failure will increase detection of worsening of symptoms and avoid future hospitalization of the HF-patients.

NCT ID: NCT03035565 Completed - Clinical trials for Heart Failure NYHA Class III

Cognitive Intervention to Improve Memory in Heart Failure Patients

Memoir-HF
Start date: February 22, 2017
Phase: N/A
Study type: Interventional

Cognitive Intervention to Improve Memory in Heart Failure patients

NCT ID: NCT03005184 Withdrawn - Clinical trials for Heart Failure NYHA Class III

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

Start date: September 2017
Phase: Phase 2
Study type: Interventional

This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)